Bitcoin miners are an important yet often overlooked section of the cryptocurrency community. While people like Michael Saylor or Jack Dorsey grab the headlines, Bitcoin miners are in the background, securing a network that processes billions of dollars in value annually. As mining plays a key role in Bitcoin, it is important to have an avenue for professionals to interact and discuss industry-related issues. Not only does this foster a sense of community, but it promotes cross-pollination of ideas and innovation in the Bitcoin mining industry. However, Bitcoin miners have often lacked the opportunity to interact with colleagues and industry players. Not that this is surprising; cryptocurrency—and cryptocurrency mining itself—is still a nascent industry. Fortunately, things are better now—with events like the Mining Disrupt Conference bringing together members of the Bitcoin mining collective to discuss, share ideas, and learn from each other. Started in 2018, Mining Disrupt has become the mining industry’s premier event, drawing a diverse group of people from all over the world. How It All Started In the early days, Bitcoin mining was something of a hobby for computer geeks or random people excited by the prospect of “magic Internet money.” Enough that someone (infamously)paid for a pizza with 10,000 BTC. But, with the 2017 bull run, and the subsequent increase in Bitcoin’s valuation, mining became a red-hot sector. For instance, Bitmain (one of the earliest providers of Bitcoin mining hardware) made between $3 to $4 billion in profits in 2017 alone—thanks to growing interest in Bitcoin mining operations. With the growing expansion of Bitcoin mining, miner collectives started popping up everywhere. One of them was the Blockchain Miners Group, an online community for miners created by Michael Cruz early in 2017, before the first bull run of that year. Hosted on the Telegram social network, the Blockchain Miners Group was among the first all-miner online communities. There, members from different parts of the world could interact with colleagues, share tips, and have insightful discussions about the industry. As Bitcoin mining continued to attract new entrants, the Blockchain Miners Group expanded its size. Soon enough, its members called for more IRL interaction, leading to talk of a conference for Bitcoin miners. Thus, the Mining Disrupt conference was born. Building the World’s Biggest Bitcoin Mining Meetup Bitcoin mining is one of the world’s least-understood professions. To many, miners are nothing more than individuals burning ridiculous amounts of energy to “win new bitcoins.” In fact, it wouldn’t be a stretch to say miners are the most-vilified section of the crypto industry. But the average Bitcoin miner is no different from any other worker. They have an important job: processing transactions and securing the Bitcoin blockchain. With Bitcoin’s average daily transaction volume entering millions, miners are an indispensable part of the Bitcoin network. [Image source] Every profession needs a platform for members to meet and interact. More importantly, professional meetups are where innovations, tools, and groundbreaking insights are shared. The Mining Disrupt Conference arose out of a need to have greater synergy between blockchain miners. Previous attempts at coordinating IRL miner meetups had faced difficulties, particularly because Bitcoin mining is a highly mobile industry and miners are often spread across different parts of the world. However, Mining Disrupt benefited from a visionary team and succeeded in its goal of bringing the Bitcoin mining community together. The first conference, held in 2018, was a massive success with thousands of investors, vendors, and professional miners in attendance. From the start, Mining Disrupt aimed to provide maximum value to attendees. The conference hosted key players, including power grid suppliers, renewable energy providers, and manufacturers of mining hardware, such as GPUs and ASICs. It also welcomed innovators and disruptors sharing novel insights to make the Bitcoin network more secure. From its humble origins, Mining Disrupt has grown to become the world’s largest B2B Bitcoinmining conference and expo. Every year, thousands of professionals and companies in theBitcoin mining industry meet in a massive convention center and discuss the state of theindustry. No other group has benefited more from Mining Disrupt than the miners who the event was created to serve. With access to exhibitions, keynote speeches, and group interactions, mining professionals leave each conference better than they arrived. Other players, like mining equipment providers, have also benefited. With the chance to display cutting-edge technology to arguably the world’s largest all-miner audience, companies have been able to increase their reach and drive conversions. Announcing Mining Disrupt 2022 The Bitcoin mining landscape has changed considerably since the early days. For example, the19th million bitcoin was recently mined, a development with great implications for the future of the world’s largest cryptocurrency. Then there’s the “Change The Code” campaign, a movement backed by Ripple, hoping to switch Bitcoin from proof-of-work consensus to proof-of-stake. Increasing regulatory pressure is also cause for concern(China banned Bitcoin mining late last year). More than ever, the Bitcoin mining community needs to meet and discuss current challenges as well as future opportunities. This makes the 2022 Mining Disrupt conference, which will run between July 26-28 at the Miami Airport Convention Center in Miami, a must-attend for everyone in the cryptocurrency mining industry. As usual, Mining Disrupt will feature the best of the Bitcoin mining community. Moreover, this year’s edition counts JSBit as sponsors and plans to host thousands of attendees, investors, and vendors. The team behind Mining Disrupt has gone to great lengths to make this year’s edition better than previous ones. With new additions, like an ASIC Museum and a new Whale Guest Pass, Mining Disrupt 2022 promises to give attendees maximum value. Who Should Attend the Mining Disrupt Conference? If you’re a Bitcoin miner, then attending the Mining Disrupt conference is a no-brainer. You’d be hard-pressed to find any other opportunity to connect with the Bitcoin mining community other than this. Not only will you benefit from expert talks, but interacting with experienced Bitcoin miners can get you started on the right path. As one of last year’s attendees put it: “Everyone you should be talking with, as a miner, is here.” Perhaps you’re nursing an interest in starting a mining operation, but want to test the waters first. Attending the conference will expose you to the realities of mining and give you the information you need to start. You’ll also benefit from interacting with the world’s best mining tooling companies exhibiting at Mining Disrupt. And if you don’t fall into any of these categories? You’re still welcome! Mining Disrupt is a place to learn about Bitcoin mining from professionals with skin in the game, not armchair experts. If you’re a Bitcoin enthusiast looking to understand how mining sustains the Bitcoin network, here’s your chance. Companies involved in the Bitcoin mining industry will find the Mining Disrupt conferencetailored to their needs. The organizers have created a series of affordable exhibition options fororganizations of different sizes. Does your company have a new solution you think the Bitcoin mining industry needs? This is your chance to get it across to the right audience. Head over to the official Mining Disrupt website to buy your tickets and find more details about our exhibitions! Bottom Line The Bitcoin mining community is a close-knit collective, with everyone ready to help the other. If you’re new to the industry or a veteran looking to connect with colleagues, consider joining the Blockchain Miners Group. We have resources for you to help ease your journey into the amazing world of cryptocurrency mining. Besides earning money, you can be part of a new movement to create a fairer monetary system for all.

CWCBExpo is a leading B2B marketplace for networking within the cannabis community. Become a part of the interactive educational sessions, hold unique product displays, participate in panel discussions, and seek the phenomenal opportunities offered by the CWCB platform. The conference is being held on June 2-4, 2022 as an in-person event for the hemp and cannabis business community in New York. From discovering the more creative products being showcased to making launch announcements, the CWCBExpo is the center place of all cannabis business. Industry thought leaders and eminent personas of the cannabis arena from New York and around the globe will be gracing the event with their presence. They will share their insights and valuable suggestions that will pave the way for the future of the cannabis business. The event will also host a spectacular assembly of speakers who will discuss all the important aspects of the cannabis spectrum ranging from regulations to the medical and adult use of cannabis. The line-up of speakers consists of influential personalities namely:

• Tremaine Wright is the Chairwoman of the New York State Cannabis Control Board and a former member of the New York State Assembly. She looks into the regulatory and tax policies regarding medical and adult-use cannabis in New York State.
• Gia Morón is the President of Women Grow and the Founder and CEO of GMV Communications. She supervises the company’s operations and strategic partnerships.
• New York City Mayor Eric Adams Delivering a Keynote Address

Some important topics at the conference:

• Trends and opportunities in the cannabis and hemp industries
• Latest marijuana and hemp investment trends that get the attention of Wall Street
• Discussion with experts about the infused, edibles and the consumer packaged goods sector
• Discussions by dispensary owners, retailers, and designers about owning and maintaining a dispensary
• Licensing & The Illicit Market
• Challenges of getting into the cannabis and hemp business and being successful

Attendees can meet the experts and leading exhibitors to interact and foster business ties with each other. The workshop and conference program being held at the Expo are knowledge houses to impart essential information and news about the cannabis industry. The thought leadership hosts will be sharing the stage along with some distinguished cannabis experts. They will cover essential topics like Investing and Industry Progress, Policy and Legislation, Cannabis and Lifestyle, for the three days subsequently. To learn more, please visit https://cwcbexpo.com/.

• Prime Harvest is a California-based tech-driven full-service cannabis corporation focused on direct-to-consumer operations, licensing acquisition, compliance management, and state-wide delivery
• Prime Harvest fuses integrity into operations, dedicated to redefining the customer experience, being a force for good within the communities they serve, while building a valuable enterprise
• Member of Community Alliance Program (“CAP”), supports education, arts initiatives, and military veteran organizations in local Southern California
• Company launched Jaxx Cannabis in 2019, sales increased by 34% in early 2020, hit record 63% gross margin in Q1-2020

From its humble beginnings in 2017 as a cannabis producer in San Diego, Prime Harvest, a technology-driven full-service cannabis corporation, has risen to prominence as a leader in California’s cannabis industry while focusing on enhancing the customer experience, diversity, and giving back to the community. Prime Cannabis is horizontally diversified across the entire cannabis value chain with business activities focused on direct-to-consumer operations, licensing acquisition, compliance management, and state-wide delivery. The company continues to expand its footprint throughout California with a proven long-term strategy of investing in the growth and scale of licensed assets while leveraging the power of data-driven technology across its operations. At the same time, Prime Cannabis focuses on community, the environment, and promoting diversity throughout the organization. Led by a team of reputable experts in their respective fields, the company dedicates activities to setting new operational standards that emphasize sustainability, accountability, and community. As a proud member of the Community Alliance Program (“CAP”), Prime Harvest supports efforts to improve education, provide resources for military veterans, and promote the arts for children and adults in local communities. As an advocate of cannabis access for medical patients, CAP also leads educational initiatives to help explore the healing attributes of cannabis to treat epilepsy, Post-Traumatic Stress Disorder (“PTSD”), cancer, Chronic Traumatic Encephalopathy (“CTE”), chronic pain, and autism. Since its early beginnings in 2017 as the “Olive Tree Wellness Center” – a patient association serving the San Diego community – Prime Harvest has provided compliant, first-in-class cannabis products and experiences. Hampered by early legislation limitations that impacted San Diego operations, the company spun its strategy to overcome these challenges and maximize the opportunities that came with operating within the particularly conservative and underserved market. As a result, Prime Harvest rebuilt its operations and launched Jaxx Cannabis – its flagship brand and dispensary. Jaxx Cannabis enjoyed immediate success, particularly as a result of coronavirus mandates that permitted cannabis dispensaries to remain open. As a result, Jaxx Cannabis drove substantial company growth throughout 2020, providing evidence that the industry is resilient to recessions and economic downturns. Sales increased by 34% at the start of 2020, hitting a record 63% in gross margin by the first quarter (https://ibn.fm/Mv7eq). Prime Harvest is favorably positioned as a leader in California’s cannabis industry, backed by a strong business strategy and anchored by its commitment to community, diversity, and becoming California’s preferred cannabis retailer. The company’s commitment to accountability is fused throughout its operations as it strives to continue growing financially and providing shareholder value. For more information, visit the company’s website at www.PrimeHarvestInc.com. NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest are available in the company’s newsroom at https://ibn.fm/PRIME

• WHO director-general warns COVID-19 is “most certainly not over”
• KNOS building reputation for effective, advanced, state-of-the-art air filtration and purification systems
• Company also offers Kronos(R)-designed graphene N95 face masks made in U.S. at NIOSH-certified facility

While mask mandates have been lifted and life appears to be returning to normal in many places around the world, the COVID-19 pandemic is “most certainly not over,” reported Tedros Adhanom Ghebreyesus, director-general of the World Health Organization (https://ibn.fm/8YfkT). The need for continued vigilance has spurred many companies, including Kronos Advanced Technologies (OTC: KNOS), that are working to provide people with protection against the deadly virus and its variants. The warning came, reported U.S. News & World Report, “despite a decline in reported cases since the peak of the omicron wave. [Tedros] told governments that ‘we lower our guard at our peril.’” The report noted that the head of WHO, while opening the organization’s annual meeting in Geneva, said “that ‘declining testing and sequencing means we are blinding ourselves to the evolution of the virus.’ He also noted that almost 1 billion people in lower-income countries still haven’t been vaccinated.” In a weekly report on the global situation, “WHO said the number of new COVID-19 cases appears to have stabilized after weeks of decline since late March, while the overall number of weekly deaths dropped,” the article continued. “While there has been progress, with 60% of the world’s population vaccinated, ‘it’s not over anywhere until it’s over everywhere,’ Tedros said. ‘Reported cases are increasing in almost 70 countries in all regions, and this in a world in which testing rates have plummeted.’” Kronos Advanced Technologies has built a reputation for offering some of the most effective, advanced, state-of-the-art air filtration and purification systems available. The proprietary Kronos(R) systems fully remove harmful allergens, bacteria, viruses (including the flu) and even gasses from indoor breathing spaces, including healthcare and other settings. In addition to air filtration systems, Kronos also offers Kronos(R)-designed graphene N95-compatible face masks made in the United States at a NIOSH-certified facility (https://ibn.fm/vaA5J). Kronos recently announced test results from Nelson Labs demonstrating significantly enhanced bacterial filtration efficiency (“BFE”) and viral filtration efficiency (“VFE”). According to the update, Kronos’ designed and U.S.-manufactured 5-ply graphene face masks remove 99.9% of bacteria and virus particles, compared to the common and far less efficacious ASTM level 3 mask. The company believes that, with BFE and VFE levels over 99.9%, these are the highest filtration efficiency numbers for any face masks in the market. “Our goal is to provide the best available protective face masks on the market for those in higher-exposure risk environments, with the best technology available,” said Kronos CEO Michael Rubinov (https://ibn.fm/A1xB2). “Our Kronos graphene technology achieves this not only as of the highest protection properties but also by completely reducing the number of viable bacteria and virus particles that are able to pass through the mask materials to zero.” Kronos’ patented medical-grade technology is tested as the most-effective, clean-air solution on the market. Kronos filters particles down to .0146 micron (.0146μm), much smaller than the 3 microns (0.3μm) of a traditional HEPA filter. Kronos not only collects but destroys air pollutants; the company’s Kronos AIR 5G(R) Air Purifiers use about 30,000 volts inside to actively destroy 99.99% of all airborne bacteria, mold, and virus particles. The Kronos face mask is the only five-ply graphene mask made in the United States. Kronos Advanced Technologies is exploring broad ranges of additional markets for standalone and embedded Kronos CORE technology-based devices, including schools, universities, healthcare facilities, operating rooms, manufacturing clean rooms, and automobiles and commercial aircraft cabins. For more information, visit the company’s website at www.KronosATI.co. NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

 

• Corporate issuers are spending over $675,000 annually on climate-related disclosures
• Institutional investors, on the other hand, spend about $1.4 million to collect, analyze and report climate data
• Correlate Infrastructure Partners Inc. seeks to offer deep financial savings and energy efficiency by reducing site-specific energy consumption and deploying clean energy generation
• Through its offering, it aims to help companies and investors cut down on costs associated with climate-related disclosures while also helping them adhere to the new rules and guidelines

Companies worldwide are facing increasing pressure to provide climate-related disclosures. Regulators have been at the forefront of demanding these releases in a move that seeks to foster accountability and push for a more sustainable and greener planet. Most notably, the United States Securities Exchange Commission (“SEC”) has been on an aggressive push for these disclosures, even unveiling its proposed rules back in March 2022 (https://ibn.fm/hihTE). It is estimated that corporate issuers are spending over $675,000 annually on climate-related disclosures. In addition, it is estimated that institutional investors are spending close to $1.4 million to collect, analyze and report climate data, which is a hefty sum that can be channeled towards other areas of operation, including, but not limited to renewable energy. Correlate Infrastructure Partners (OTCQB: CIPI) has proven to offer deep financial savings and energy efficiency across the commercial sector. With an opportunity pipeline of over $100 million in commercial projects and more than $20 million in awarded backlog, this company seeks to leverage the U.S. portfolio energy optimization market, which is currently valued at $290 billion. In a study conducted by the SustainAbility Institute by ERM, it was discovered that corporate issuers spend over $677,000 every year on climate-related disclosure activities. Greenhouse gas (“GHG”) analysis accounted for the highest expenditure at $237,000 on average, while climate scenario analysis accounted for $154,000. In addition, climate risk management control costs $148,000 on average, which, in total, was not far off from the SEC’s estimates which stood at $640,000. The study, which involved 39 corporate issuers across multiple U.S. sectors, with a market cap range of under $1 billion to over $200 billion, along with 35 institutional investors representing a total of $7.2 trillion of assets under management (“AUM”) was aimed at highlighting the costs incurred by enterprises in the quest for environmental accountability. “This survey shows that both companies and investors recognize the benefits of disclosing their climate-related activities,” noted Mark Lee, the Director of SustainAbility Institute by ERM. “It also offers a rare glimpse into issuer and investors’ current investments in measurement, analysis, and disclosure of climate-related information, which will be a valuable resource for organizations considering their response to the proposed SEC rules,” he added. With this push by the SEC, companies and investors are being urged to adopt greener energy alternatives and lower their overall carbon footprint. Correlate Infrastructure Partners is well-positioned to satisfy this growing need. With its unique value proposition, companies are bound to reap the benefits of its infrastructure, ranging from cost savings to lower carbon emissions and meeting the changing regulations being implemented with every passing day. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• A global innovator in drug delivery platforms, Lexaria has developed a patented technology, DehydraTECH(TM)
• Through research, Lexaria has evidenced that DehydraTECH enhances the efficiency and speed of orally- administered fat-soluble active pharmaceutical ingredients (“APIs”)
• Lexaria is consistently enhancing the delivery of APIs that affect current oral formulations: speed of onset, limited absorption, and low membrane permeability
• Lexaria has conducted numerous ground-breaking studies, some of which open up the possibility of fast-acting oral products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking

Oral formulations account for approximately 90% of the global share of all pharmaceutical formulations made for human use. Statistics also show that about 60% of all established, commercially available small-molecule drug products today and approximately 84% of all best-selling pharmaceutical products are orally administered. Oral drug administration is preferred because it offers numerous advantages over other delivery methods (for instance, intramuscular, subcutaneous, intravenous, and inhalation), not the least of which is high compliance of patients. Additionally, the drugs can be used to offer localized treatment of affected regions within the gastrointestinal tract. “Despite these advantages, the development of oral formulations presents several challenges, which are mainly attributed to the physicochemical properties of drugs, including poor water solubility and membrane permeability. In addition, the absorption of drugs can be limited by their poor chemical and biological stability, as well as by physiological barriers, including pH, efflux transporters, and metabolic enzymes,” reads a 2021 review article published in the Frontiers in Pharmacology Journal (https://ibn.fm/Fj0TC). In understanding the shortcomings of orally administered drugs, Lexaria is rising to the occasion, developing a drug delivery technology that solves the aforementioned challenges. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed DehydraTECH(TM), a patented technology which enhances the efficiency and speed of orally-administered fat-soluble active pharmaceutical ingredients (“API”). “DehydraTECH combines lipophilic APIs with specific fatty acid and carrier compounds, thereby improving the way APIs enter the bloodstream while increasing the effectiveness of fat-soluble active molecules allowing lowering overall dosing and promoting healthier oral ingestion methods,” Lexaria explained in its 2021 annual report (https://ibn.fm/W2hsW). The company began developing DehydraTECH in 2014 and has since strengthened the technology as well as broadened its possible applications. Now, Lexaria’s website notes, the technology “can be applied to many different drugs and other active ingredients such as vitamins in oral formats including tablets, capsules, oral suspensions – and even foods, beverages, and topical preparations.” Lexaria has also conducted in vitro and in vivo human and/or animal studies that have evidenced the technology’s ability to mask unwanted tastes, improve the speed of onset, increase bioavailability and brain absorption, and lower dosing – thereby reducing drug administration costs – of APIs. So far, Lexaria has explored how DehydraTECH improves APIs, not limited to, cannabidiol (“CBD”), oral nicotine, and antiviral drugs, with the company describing its oral nicotine investigations as “ground-breaking studies to open doors previously closed to disruptive new technology, including the possibility of potent and fast-acting ingestible products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking” (https://ibn.fm/ysLHG). In a series of animal studies staggered between 2018 and 2021, Lexaria evidenced that DehydraTECH delivered considerable nicotine absorption performance improvements compared to controls. The technology resulted in faster delivery of the compound, a higher quantity of peak nicotine delivered to the bloodstream, greater bioavailability, and higher brain absorption (as evidenced by high levels of nicotine in the brain). In its latest animal study, whose results the company released last year, Lexaria revealed that DehydraTECH was between 10x to 20x faster in achieving peak delivery of oral nicotine to the bloodstream than controls. It also attained peak nicotine levels that were up to 10x higher than controls (https://ibn.fm/uBCLc). Now, Lexaria is focusing on the human nicotine study, NIC-H22-1, with dosing expected to begin this summer. The company hopes that the use of DehydraTECH-nicotine pouches –will help avoid harmful outcomes associated with smoking tobacco, a source of nicotine. Tobacco use causes 480,000 deaths (including passive smokers) annually in the United States (https://ibn.fm/dbT1L). Globally, tobacco claims over 8 million lives every year, 7 million of which result from direct tobacco use, while about 1.2 million are caused by the inhalation of secondhand smoke (https://ibn.fm/ZM7lE). In its quest to promoting healthier alternatives to traditional orally administered drugs as well as morbidity-causing practices such as smoking, Lexaria is simultaneously tapping into multibillion-dollar industries. Valued at an estimated $5.9 billion in 2022, the global nicotine pouches market is projected to grow at a CAGR of 31% to reach $29.6 billion by 2028 (https://ibn.fm/krqIF). Similarly, the oral drug delivery market, which was valued at $100.05 billion in 2018, is projected to grow at a CAGR of 6.99% to reach $150.06 billion by 2024 (https://ibn.fm/wTcW1). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Life science companies and professionals are invited to attend Dynamic Global Events’ (“DGE”) 2nd KOL Engagement Forum, livestreaming June 1-2, 2022. A pioneer in organizing networking events, Dynamic Global Events focuses on delivering high-quality data and networking avenues to the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The forum is designed for medical and life science professionals to create strong networking ties and cultivate strong long-term relationships with the most influential thought leaders in the industry. In these uncertain times when there is growing distrust for institutions, these respected partnerships will foster confidence and lend credibility to the products. KOLs are expected to play a significant role in each stage of the drug cycle. The event timings for both days is 9:15am to 3:15pm. The 2-day event will witness speeches, keynotes, and discussions from leading industry life science professionals on how to build a trusted alliance with KOLs. The 2nd KOL Engagement Forum offers this unique opportunity to young and aspiring pharmaceutical, biotech, and medical device professionals to engage with KOLs. This event is designed for life science companies in the wake of the changing scenario where regulations become more strict, the demand for personalized medical products and treatment is growing, and so is the need for better connections with KOLs as well as new thought leaders. Key Reasons to Attend:

• Panel discussions, keynotes, and fireside chats on KOL engagement in virtual and hybrid environments
• Learn and understand the novel techniques of dividing up MSL territories
• Avail of the cross-functional engagement plan and align with the team members to deliver the best experience
• Recognize the most important metrics – and develop new ones
• Build long-term strong networking ties through emotional intelligence
• Build high-performance teams in a hybrid environment
• Reliable strategies for identifying and overcoming the biggest outreach hurdles

The introduction will be given by the Chairperson Bryan N. Bischel, PhD. Field Director, MSLs, East Region Eye Care at AbbVie. With more than 15 years of progressively responsible medical affairs experience, Bryan is an accomplished senior medical affairs professional. He is a strategic thinker and a thought leader with high-performance skills to hire, train, and direct high-impact MSL teams. To learn more, please visit https://ibn.fm/TZnZR.

The Social Media & Influencer Strategies Summit promises to bridge the “best of both worlds,” conflating two conferences set to be held over four days. Organized by GSMI Events, the virtual event scheduled for June 7-10 includes a two-day Social Media Summit set for June 7 and 8, in which the speakers and panelists will focus their talks on social media marketing and content strategy, and an Influencer Summit subsequently slated for June 9 and 10. The latter will feature influencer-marketing-focused case studies and talks delivered by leading figures in the influencer segment. Attendees will get to hear from 50 speakers drawn from leading brands, who will share their proven social media and influencer marketing strategies. Their presentations, panel discussions, and case studies are designed to assist those in attendance to:

• Understand all the attributes of a successful social media strategy that positions a brand for success
• Maximize the performance of their social media and influencer marketing programs
• Probe and audit their current social media initiatives
• Experience and see what is driving success at various companies and inspire innovation as a result
• Enrich their arsenal of tools, resources, and connections to keep their brand at the leading edge of the ever-changing trends in the social media and influencer spaces
• Learn how to tap into the right influencers for their brand, create long-term collaborative relationships, and assess the impact of campaigns on their broader business objectives

Kickoff The Social Media Summit will kick off on June 7 with a panel discussion entitled “Learning to take creative risks to find success on social,” with inputs from Markeia McCarty – Marketing Manager at Hunters Entertainment, Glenn Woods – a Senior Social Media Manager working with Hulu, and Christina Kelleher – the Head of Social Media at Wayfair. This panel discussion will kickstart a day of presentations exploring the best practices for brand’s TikTok strategy and building a data-driven social media strategy, as well as topics such as creating a seamless omnichannel experience, how brands leverage cultural moments for brand awareness, and more. Day 2 The second day will feature two panel discussions as well as presentations exploring how to track and report ROI to reflect social’s business impact, reaching audiences with engaging, on-brand videos, how to define brand identities, the role of community in authentic brand storytelling, and more. Day 3 & 4 The third and fourth days of the event – the first and second days for the Influencer Summit – will include talks and case studies from speakers working with leading brands and agencies in the influencer space. Included in the agenda are topics such as how to integrate shoppable content in influencer marketing campaigns, setting up campaigns for success, integrating influencer marketing into a larger marketing mix (panel discussion), and how to enhance influencer effectiveness with language and visual choices, just to mention a few. Interspersed between the various presentations are breaks meant to facilitate networking and interactions with vendor speakers, and GSMI has designed its virtual event platform around this. The platform will feature an exhibit hall, session rooms, and a portal specifically meant to enable attendees to chat directly with other attendees and set up 1:1 meetings. In addition to the presentations, GSMI Events will make available on-demand sessions, offering visitors and attendees access to talks whenever and wherever they want. These never-before-seen video sessions will cover unique topics, providing new insights even to those who will attend the four-day summit. To learn more, please visit https://socialmediastrategiessummit.com/virtual-conference-june-2022/

The Cannabis World Congress & Business Exposition (CWCBExpo) will be held between June 2-4, 2022, at the Javits Convention Center, Hall 3A, in New York City. Industry heavyweights, the foremost innovators, and pioneering thought leaders will take the stage to discuss emerging trends in cannabis, hemp, and allied sectors. The expo will provide a high-quality business-focused attendee base located in the premier East Coast US cannabis and hemp market. The three-day event will feature an Inside the Industry: Thought Leadership Series in an interactive “Talk Show” format. Co-hosts will include Carl Cameron, veteran journalist and former FOX News reporter; Faye Coleman, Founder and CEO of Pure Genesis, cannabis pioneer and entrepreneur Calvin Frye, and Gretchen Gailey, Chief Strategist at CWCBExpo. The Thought Leadership series will address distinct aspects of the sector each day. Day 1, Thursday, will focus on Investing and Industry Progress, Day 2 will address Policy and Legislation, and Day 3 will explore new developments in Cannabis and Lifestyle. The sessions will be educational and relevant to both the local landscape and the national outlook. The conference program will also feature two keynote conversations with Chris Beals, CEO of Weedmaps, along with Mona Zhang, States Cannabis Policy Reporter, POLITICO, on Thursday, Jun 2; and with Nick Kovacevich, CEO of Greenlane Holdings, along with Tim Seymour, Co-host, CNBC Fast Money. In addition to the wide array of expert speakers and eminent business people in attendance, the summit will host hundreds of exhibitors showcasing cutting-edge product innovations and the latest services. The event shall also host a Networking Mixer on Thursday, June 2, from 5 – 7 pm, sponsored by Weedmaps, so that attendees can network or relax ahead of the second day of the conference. On Friday, June 3, from 6 – 10 pm, CWCBExpo will host the Industry Yacht Party, where attendees can eat, drink and dance with their peers while savoring the majestic New York City skyline. This is a premier networking and deal-making opportunity. To attend either or both events, registered attendees must purchase a Networking Mixer Ticket or an Industry Yacht Party Ticket. Get your tickets now at the best price! Why wait? Cannabis Week, anchored by CWCBExpo, will take place from Monday, May 30 to Sunday, June 5, 2022, and will foster collaboration between the entire cannabis industry through industry deep dives, networking events, and lead-generation opportunities.  Several events will take place during the week throughout New York City. To learn more about Cannabis Week, event itineraries, available offers, and discounts, visit  https://cwcbexpo.com/cannabis-week For more information about the CWCBExpo, please visit https://cwcbexpo.com/

On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma focuses on palliative uses of psychedelics for “PTSD, Parkinson’s, and other rare neurological disorders.” In teaming up with TrPR. Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s Disease. Psilocybin’s journey from magic mushrooms to potential life savers has been a long, strange trip. Used for millennia in spiritual quests, associated with hippies and currently outlawed by the US Government (though legal in Oregon and decriminalized in various cities and states), Silo Pharma still believes in these medicinal mushrooms. But why? The National Center for Biotechnology Information (at The National Library of Medicine), offers answers:

• In addition to the known recreational, spiritual, and religious uses of magic mushrooms, there is significant medicinal value, as evidenced by anecdotal reports and scientific studies.
• With the increase in the rate of mental disorders globally, now exacerbated by COVID-19, psychedelic-assisted psychotherapies, particularly psilocybin-assisted psychotherapies, may alleviate some of the challenges that face conventional psychiatric medicine.
• To date, over 27,000 scientific articles have been published on psychedelic drugs, with over 1000 particularly on psilocybin. Currently, psilocybin is the most studied psychedelic.
• Of all psychedelic drugs, psilocybin is reported to have the most favorable safety profile…the vast evidence-based data that exist for psilocybin alone suggest that psilocybin may be the most efficacious psychedelic drug for treating [numerous] disorders…
• In addition to having the potential to treat mood and anxiety disorders, psilocybin has also demonstrated analgesic effects as evidenced by numerous clinical studies on the treatment of cluster (“suicide”) headaches, intractable phantom-limb pain (“PLP”), and chronic pain. … In some cases, psilocybin was comparable to or more efficacious than traditional medications such as opioid analgesics…
• Globally, the psychedelic therapeutic market is predicted to reach a valuation of $6.8 billion by 2027, from USD 2 billion in 2019, at a growth rate of 16.3%. The neurogenic market including mental health drugs, therapeutic services, neurodegeneration drugs and cognitive enhancement was valued at USD 373 billion.

Lowe H, Toyang N, Steele B, et al. The Therapeutic Potential of Psilocybin. Molecules. 2021;26(10):2948. Published 2021 May 15. doi:10.3390/molecules26102948 Psilocybin’s potential in combating neuroinflammation could change medicine as currently practiced, particularly regarding dementia and CNS disorders. According to “Psychedelics for Brain Injury: A Mini-Review,” neuroinflammatory states occur with diseases such as Alzheimer’s, and Parkinson’s. “There are currently three main classes of anti-inflammatory drugs: non-steroidal anti-inflammatory drugs (NSAIDs), steroids such as prednisone, and biologics which act like sponges to “soak up” inflammatory cytokines. Psychedelics may represent a fourth class of anti-inflammatory drug.” Eric Weisblum, Silo’s CEO, said, “Successful dosing and collection of blood samples from enrolled [TrPR] patients is an important milestone that demonstrates the progress being made … to examine the effects of psilocybin as an anti-inflammatory agent.” Silo’s commitment to psilocybin and anti-inflammatory research includes:

• Executing an option agreement with the University of Maryland, Baltimore studying novel system-homing peptides that could potentially “home to the inflamed CNS [central nervous system] and can differentiate between diseased and healthy CNS tissue.” This could be highly beneficial to multiple sclerosis (“MS”) patients as current treatments are “… given orally or parenterally and their use is associated with various side effects … a specific CNS-homing peptide would enhance the efficacy of the treatment and help limit the side effects significantly.(1) According to Silo, “These peptides also have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. In addition, these novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.”
• Collaborating with the University of California San Francisco (“UCSF”) to study the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, bipolar disorder, and chronic back pain. Weisblum says, “Inflammation has specifically been implicated in the pathophysiology of Parkinson’s Disease, chronic pain, and bipolar disorder.  Psilocybin and related compounds have shown strong anti-inflammatory effects in non-human animals, raising the possibility that reducing inflammation is a possible mechanism underlying psilocybin’s positive treatment effects in multiple disorders…”
• Teaming with the University of Maryland, Baltimore, for patented Homing Peptides to target Rheumatoid Arthritis. According to a Silo news release, “The ability … to target inflamed endothelium suggests [homing peptides] could be used to target drug delivery to the diseased joints. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. These peptides have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. The peptides could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.

(1) Acharya, Bodhraj et al. “A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis.” Molecular and cellular probes vol. 51 (2020): 101530. doi:10.1016/j.mcp.2020.101530 For Silo Pharma’s most recent news, click here. Silo Pharma 560 Sylvan Avenue, Suite 3160 Englewood Cliffs, NJ 07632 For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO